Presentation
5 March 2021 Photodynamic therapy-based combination regimen with EP4 inhibitors attenuates metastatic behavior in ovarian cancer
Author Affiliations +
Abstract
Ovarian cancer typically spreads throughout the peritoneal cavity, and despite standard of care treatments (surgical debulking and chemotherapy), the five-year relative survival rate remains below 50%. The use of antibody-photosensitizer conjugates (photoimmunotherapy) has emerged as a promising modality to achieve targeted photosensitizer delivery to ovarian cancer cells. In this study, we investigate epithelial growth factor (EGFR)-targeted PIT coupled with inhibition of prostaglandin E2 receptor 4 (EP4), a G-coupled-receptor that contributes to cancer progression and intracellularly transactivates EGFR. This potent triple combination significantly attenuates the metastatic behavior of ovarian cancer cells through simultaneously inducing photochemical damage and modulating protein expression.
Conference Presentation
© (2021) COPYRIGHT Society of Photo-Optical Instrumentation Engineers (SPIE). Downloading of the abstract is permitted for personal use only.
Aaron Sorrin, Jocelyn Reader, Cindy Liu, Julia Cicalo, Danial Najafali, Dana Roque, and Huang Chiao Huang "Photodynamic therapy-based combination regimen with EP4 inhibitors attenuates metastatic behavior in ovarian cancer", Proc. SPIE 11628, Mechanisms and Techniques in Photodynamic Therapy and Photobiomodulation, 1162805 (5 March 2021); https://doi.org/10.1117/12.2581786
Advertisement
Advertisement
KEYWORDS
Ovarian cancer

Photodynamic therapy

Photoimmunotherapy

Cancer

Receptors

Clinical trials

In vitro testing

Back to Top